Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04514497 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer | active not recruiting | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04782752 | Non-ablative Oligofractionated Radiation Therapy Before Surgical Transplantation As Radiovaccination(NORThSTAR) | recruiting | N/A | 30 | Marc de PerrotOTHER |
| 1 |
| Sep 10, 2026 |
| clinicaltrials |
| NCT04958811 | Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC | active not recruiting | Phase 2 | 29 | Georgetown UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05557045 | A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | active not recruiting | Phase 1 | 98 | Jazz PharmaceuticalsINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06266299 | A Study of KK2269 in Adult Participants With Solid Tumors | recruiting | Phase 1 | 101 | Kyowa Kirin Co., Ltd.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT06269133 | Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants | active not recruiting | — | 1,000 | Regeneron PharmaceuticalsINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06687369 | A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) | active not recruiting | Phase 3 | 726 | mAbxience Research S.L.INDUSTRY | 24 | Sep 10, 2026 | clinicaltrials |
| NCT07462377 | A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC | recruiting | Phase 1 | 110 | EpiBiologicsINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07640789 | A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) | recruiting | Phase 3 | 418 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT01708954 | Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 125 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03040973 | Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone | active not recruiting | Phase 2 | 29 | Novartis PharmaceuticalsINDUSTRY | 11 | Sep 9, 2026 | clinicaltrials |
| NCT04351555 | A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer(NeoADAURA) | active not recruiting | Phase 3 | 358 | AstraZenecaINDUSTRY | 25 | Sep 9, 2026 | clinicaltrials |
| NCT05091567 | A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer(IMforte) | active not recruiting | Phase 3 | 660 | Hoffmann-La RocheINDUSTRY | 13 | Sep 9, 2026 | clinicaltrials |
| NCT05361395 | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | active not recruiting | Phase 1 | 184 | AmgenINDUSTRY | 15 | Sep 9, 2026 | clinicaltrials |
| NCT05925530 | Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)(MDT-BRIDGE) | active not recruiting | Phase 2 | 142 | AstraZenecaINDUSTRY | 11 | Sep 9, 2026 | clinicaltrials |
| NCT06097962 | Safety and Efficacy of NK510 to Treat NSCLC | recruiting | Early Phase 1 | 12 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06253871 | A Phase 1/1b Study of IAM1363 in HER2 Cancers | recruiting | Phase 1 | 383 | Iambic Therapeutics, IncINDUSTRY | 8 | Sep 9, 2026 | clinicaltrials |
| NCT06315010 | Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis(REPOSE) | recruiting | Phase 2 | 20 | MedSIROTHER | 3 | Sep 9, 2026 | clinicaltrials |
| NCT06538038 | Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients | active not recruiting | — | 200 | PrECOG, LLC.OTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06780137 | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | recruiting | Phase 1 / Phase 2 | 327 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 9, 2026 | clinicaltrials |
| NCT07310056 | The Construction and Clinical Application of an Integrated Perioperative Management System for Lung Cancer Based on Wearable Devices and Intelligent Platforms | recruiting | N/A | 126 | West China HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07541170 | A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)(KRASCENDO 3) | recruiting | Phase 3 | 400 | Hoffmann-La RocheINDUSTRY | 6 | Sep 9, 2026 | clinicaltrials |
| NCT07801430 | Station 4L Lymph Node Dissection Versus No Dissection in Clinical Stage I Solid Nodule-Type Invasive NSCLC | recruiting | N/A | 384 | Fudan UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07809256 | A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation(LPR-2) | recruiting | Phase 3 | 15 | EuroCityClinic LLCNETWORK | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07809763 | Wireless Wearable Home Prehabilitation for Older Adults With NSCLC | recruiting | N/A | 196 | West China HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04092283 | Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 660 | National Cancer Institute (NCI)NIH | 2 | Sep 8, 2026 | clinicaltrials |
| NCT05789082 | A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation(KRAScendo 170) | recruiting | Phase 1 / Phase 2 | 320 | Hoffmann-La RocheINDUSTRY | 18 | Sep 8, 2026 | clinicaltrials |
| NCT05801029 | A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations(OSTARA) | active not recruiting | Phase 2 | 60 | AstraZenecaINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT06119581 | A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer(SUNRAY-01) | recruiting | Phase 3 | 1,264 | Eli Lilly and CompanyINDUSTRY | 29 | Sep 8, 2026 | clinicaltrials |
| NCT06195527 | PEMBRO-K : Evaluation of Pembrolizumab Therapeutic Pharmacological Monitoring Benefit in NSCLC(PEMBRO-K) | recruiting | — | 75 | University Hospital, AngersOTHER_GOV | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06482073 | Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care | recruiting | — | 250 | Mayo ClinicOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06561685 | A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 340 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT06862869 | Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy | recruiting | — | 800 | Hoffmann-La RocheINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07005128 | A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)(DeLLphi-312) | active not recruiting | Phase 3 | 350 | AmgenINDUSTRY | 26 | Sep 8, 2026 | clinicaltrials |
| NCT07130786 | Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases | recruiting | Phase 2 | 150 | Ayal A. Aizer, MDOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07132190 | Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction | recruiting | Phase 2 | 60 | Ayal A. Aizer, MDOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07192991 | Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America(NECTARINE) | recruiting | — | 200 | Latin American Cooperative Oncology GroupOTHER | 4 | Sep 8, 2026 | clinicaltrials |
| NCT07718243 | Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC(BLAZE) | recruiting | Phase 1 / Phase 2 | 62 | Institute of Cancer Research, United KingdomOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806500 | Phase Ib Study of Oral R01 Monotherapy in Advanced Solid Tumors | not yet recruiting | Phase 1 | 18 | Beijing Anjianxi Bio-Medical Technology Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806604 | Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer | recruiting | — | 2,572 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | not yet recruiting | Phase 1 | 285 | Sutro Biopharma, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807722 | Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC | not yet recruiting | Phase 2 | 29 | Hubei Cancer HospitalOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807956 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 130 | AbbVieINDUSTRY | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07808138 | RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer(RADICAL-IO) | not yet recruiting | Phase 2 | 30 | The Netherlands Cancer InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT01366144 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | active not recruiting | Phase 1 | 94 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT02642042 | Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05198830 | Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
Data updated 21 days agoSource updated Sep 10, 2026source: clinicaltrials